Physician profile

Kimbra A Epps

Family · Roseburg, OR

NPI 1154406064

$226.16

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$61.22

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $59.29 2022-2023 Ozempic, Rybelsus
Organon LLC $24.95 2022
Abbvie INC. $20.31 2022
Otsuka America Pharmaceutical, INC. $20.15 2024 Rexulti
Biohaven Pharmaceutical Holding Company LTD. $19.49 2022
Daiichi Sankyo INC. $15.06 2021
Kowa Pharmaceuticals America, INC. $14.56 2023 Livalo, Seglentis
Lilly USA, LLC $14.18 2022
Pfizer INC. $13.41 2023
Coopersurgical, INC. $12.45 2022
Alfasigma USA, INC. $12.31 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kimbra A Epps

$226.16

in general payments reported 2019-2025

Years
2021-2024
Top company
Novo Nordisk INC

https://glasscript.com/doctor/10770052/kimbra-a-epps

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.